The accelerated path of ceritinib

Translating pre-clinical development into clinical efficacy

Tony S.K. Mok, Lucio Crino, Enriqueta Felip, Ravi Salgia, Tommaso De Pas, Daniel S.W. Tan, Laura Q.M. Chow

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

The discovery of anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer (NSCLC) in 2007 led to the development and subsequent approval of the ALK inhibitor crizotinib in 2011. However, despite its clinical efficacy, resistance to crizotinib invariably develops. There is now a next generation of ALK inhibitors, including two that have been approved—ceritinib and alectinib—and others that are in development—brigatinib, lorlatinib and X-396. Ceritinib and the other next-generation ALK inhibitors are more potent than crizotinib and can overcome tumor cell resistance mechanisms. Ceritinib gained US Food and Drug Administration approval in 2014 following accelerated review for the treatment of patients with ALK-positive (ALK+) metastatic NSCLC who have progressed on or are intolerant to crizotinib. In pre-clinical studies, it demonstrated more potent inhibition of ALK than crizotinib in enzymatic assays, more durable responses in xenograft models and the ability to potently overcome crizotinib resistance mutations in vitro (including the gatekeeper mutation). There is also evidence for ceritinib penetration across the blood-brain barrier. In clinical trials, ceritinib has demonstrated durable responses and progression-free survival in ALK-inhibitor–pre-treated and –naïve NSCLC patients, including high overall and intracranial response rates in those with central nervous system metastases. Selective gastrointestinal toxicity of ceritinib, such as diarrhea, nausea and vomiting is generally manageable with prophylactic medication and prompt dose reduction or interruption. Future progress in treating ALK+ NSCLC will focus on determining the optimal sequencing of therapies and strategies to overcome acquired resistance, an ongoing challenge in treating ALK-mutation–driven tumors.

Original languageEnglish
Pages (from-to)181-189
Number of pages9
JournalCancer Treatment Reviews
Volume55
DOIs
Publication statusPublished - Apr 1 2017

Fingerprint

Non-Small Cell Lung Carcinoma
ceritinib
anaplastic lymphoma kinase
Drug Approval
Mutation
Enzyme Assays
Blood-Brain Barrier
Heterografts
Nausea
Disease-Free Survival
Vomiting
crizotinib
Diarrhea
Neoplasms
Central Nervous System
Clinical Trials
Neoplasm Metastasis
Food
Therapeutics

Keywords

  • Anaplastic lymphoma kinase
  • Carcinoma
  • Ceritinib
  • Drug resistance
  • Neoplasm
  • Non–small-cell lung

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

The accelerated path of ceritinib : Translating pre-clinical development into clinical efficacy. / Mok, Tony S.K.; Crino, Lucio; Felip, Enriqueta; Salgia, Ravi; De Pas, Tommaso; Tan, Daniel S.W.; Chow, Laura Q.M.

In: Cancer Treatment Reviews, Vol. 55, 01.04.2017, p. 181-189.

Research output: Contribution to journalReview article

Mok, Tony S.K. ; Crino, Lucio ; Felip, Enriqueta ; Salgia, Ravi ; De Pas, Tommaso ; Tan, Daniel S.W. ; Chow, Laura Q.M. / The accelerated path of ceritinib : Translating pre-clinical development into clinical efficacy. In: Cancer Treatment Reviews. 2017 ; Vol. 55. pp. 181-189.
@article{fc6bfe242ee846b59c30b8f75ae0499e,
title = "The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy",
abstract = "The discovery of anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer (NSCLC) in 2007 led to the development and subsequent approval of the ALK inhibitor crizotinib in 2011. However, despite its clinical efficacy, resistance to crizotinib invariably develops. There is now a next generation of ALK inhibitors, including two that have been approved—ceritinib and alectinib—and others that are in development—brigatinib, lorlatinib and X-396. Ceritinib and the other next-generation ALK inhibitors are more potent than crizotinib and can overcome tumor cell resistance mechanisms. Ceritinib gained US Food and Drug Administration approval in 2014 following accelerated review for the treatment of patients with ALK-positive (ALK+) metastatic NSCLC who have progressed on or are intolerant to crizotinib. In pre-clinical studies, it demonstrated more potent inhibition of ALK than crizotinib in enzymatic assays, more durable responses in xenograft models and the ability to potently overcome crizotinib resistance mutations in vitro (including the gatekeeper mutation). There is also evidence for ceritinib penetration across the blood-brain barrier. In clinical trials, ceritinib has demonstrated durable responses and progression-free survival in ALK-inhibitor–pre-treated and –na{\"i}ve NSCLC patients, including high overall and intracranial response rates in those with central nervous system metastases. Selective gastrointestinal toxicity of ceritinib, such as diarrhea, nausea and vomiting is generally manageable with prophylactic medication and prompt dose reduction or interruption. Future progress in treating ALK+ NSCLC will focus on determining the optimal sequencing of therapies and strategies to overcome acquired resistance, an ongoing challenge in treating ALK-mutation–driven tumors.",
keywords = "Anaplastic lymphoma kinase, Carcinoma, Ceritinib, Drug resistance, Neoplasm, Non–small-cell lung",
author = "Mok, {Tony S.K.} and Lucio Crino and Enriqueta Felip and Ravi Salgia and {De Pas}, Tommaso and Tan, {Daniel S.W.} and Chow, {Laura Q.M.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.ctrv.2017.03.006",
language = "English",
volume = "55",
pages = "181--189",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - The accelerated path of ceritinib

T2 - Translating pre-clinical development into clinical efficacy

AU - Mok, Tony S.K.

AU - Crino, Lucio

AU - Felip, Enriqueta

AU - Salgia, Ravi

AU - De Pas, Tommaso

AU - Tan, Daniel S.W.

AU - Chow, Laura Q.M.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - The discovery of anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer (NSCLC) in 2007 led to the development and subsequent approval of the ALK inhibitor crizotinib in 2011. However, despite its clinical efficacy, resistance to crizotinib invariably develops. There is now a next generation of ALK inhibitors, including two that have been approved—ceritinib and alectinib—and others that are in development—brigatinib, lorlatinib and X-396. Ceritinib and the other next-generation ALK inhibitors are more potent than crizotinib and can overcome tumor cell resistance mechanisms. Ceritinib gained US Food and Drug Administration approval in 2014 following accelerated review for the treatment of patients with ALK-positive (ALK+) metastatic NSCLC who have progressed on or are intolerant to crizotinib. In pre-clinical studies, it demonstrated more potent inhibition of ALK than crizotinib in enzymatic assays, more durable responses in xenograft models and the ability to potently overcome crizotinib resistance mutations in vitro (including the gatekeeper mutation). There is also evidence for ceritinib penetration across the blood-brain barrier. In clinical trials, ceritinib has demonstrated durable responses and progression-free survival in ALK-inhibitor–pre-treated and –naïve NSCLC patients, including high overall and intracranial response rates in those with central nervous system metastases. Selective gastrointestinal toxicity of ceritinib, such as diarrhea, nausea and vomiting is generally manageable with prophylactic medication and prompt dose reduction or interruption. Future progress in treating ALK+ NSCLC will focus on determining the optimal sequencing of therapies and strategies to overcome acquired resistance, an ongoing challenge in treating ALK-mutation–driven tumors.

AB - The discovery of anaplastic lymphoma kinase (ALK)-rearranged non–small-cell lung cancer (NSCLC) in 2007 led to the development and subsequent approval of the ALK inhibitor crizotinib in 2011. However, despite its clinical efficacy, resistance to crizotinib invariably develops. There is now a next generation of ALK inhibitors, including two that have been approved—ceritinib and alectinib—and others that are in development—brigatinib, lorlatinib and X-396. Ceritinib and the other next-generation ALK inhibitors are more potent than crizotinib and can overcome tumor cell resistance mechanisms. Ceritinib gained US Food and Drug Administration approval in 2014 following accelerated review for the treatment of patients with ALK-positive (ALK+) metastatic NSCLC who have progressed on or are intolerant to crizotinib. In pre-clinical studies, it demonstrated more potent inhibition of ALK than crizotinib in enzymatic assays, more durable responses in xenograft models and the ability to potently overcome crizotinib resistance mutations in vitro (including the gatekeeper mutation). There is also evidence for ceritinib penetration across the blood-brain barrier. In clinical trials, ceritinib has demonstrated durable responses and progression-free survival in ALK-inhibitor–pre-treated and –naïve NSCLC patients, including high overall and intracranial response rates in those with central nervous system metastases. Selective gastrointestinal toxicity of ceritinib, such as diarrhea, nausea and vomiting is generally manageable with prophylactic medication and prompt dose reduction or interruption. Future progress in treating ALK+ NSCLC will focus on determining the optimal sequencing of therapies and strategies to overcome acquired resistance, an ongoing challenge in treating ALK-mutation–driven tumors.

KW - Anaplastic lymphoma kinase

KW - Carcinoma

KW - Ceritinib

KW - Drug resistance

KW - Neoplasm

KW - Non–small-cell lung

UR - http://www.scopus.com/inward/record.url?scp=85018318057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018318057&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2017.03.006

DO - 10.1016/j.ctrv.2017.03.006

M3 - Review article

VL - 55

SP - 181

EP - 189

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

ER -